1. Academic Validation
  2. Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

  • Invest New Drugs. 2017 Jun;35(3):397. doi: 10.1007/s10637-017-0455-y.
S Fu 1 H Hirte 2 S Welch 3 T T Ilenchuk 4 T Lutes 4 C Rice 4 N Fields 5 A Nemet 6 D Dugourd 4 S Piha-Paul 1 V Subbiah 1 L Liu 1 J Gong 1 D Hong 1 J M Stewart 7
Affiliations

Affiliations

  • 1 Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center, Houston, TX, USA.
  • 2 Juravinski Cancer Centre, Hamilton, ON, Canada.
  • 3 London Health Sciences Centre, London, ON, Canada.
  • 4 Soricimed Biopharma Inc., Moncton, NB, Canada.
  • 5 Sagecon Inc., Oakville, ON, Canada.
  • 6 CLINSIG Research Consulting Inc., Brampton, ON, Canada.
  • 7 Soricimed Biopharma Inc., Moncton, NB, Canada. jstewart@soricimed.com.
Figures
Products